{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:34:59Z","timestamp":1788780899333,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Non-<jats:named-content content-type=\"genus-species\">diphtheriae Corynebacterium<\/jats:named-content>-associated disease has been increasingly observed and often presents a conundrum to the treating physician. Analysis of antibiotic susceptibility testing data for 1,970 clinical<jats:named-content content-type=\"genus-species\">Corynebacterium<\/jats:named-content>isolates received between 2011 and 2016 revealed that empirical drug treatment options are limited to vancomycin and linezolid.<jats:named-content content-type=\"genus-species\">Corynebacterium striatum<\/jats:named-content>was the most frequently observed species during this study period, along with<jats:named-content content-type=\"genus-species\">C. amycolatum<\/jats:named-content>and<jats:named-content content-type=\"genus-species\">C. pseudodiphtheriticum\/C. propinquum<\/jats:named-content>. Low levels of susceptibility to penicillin (14.5%), erythromycin (15.1%), and clindamycin (8.7%) were observed for non-<jats:named-content content-type=\"genus-species\">diphtheriae Corynebacterium<\/jats:named-content>species, while 3.0% of isolates were not susceptible to daptomycin. Similarly, 26.9% and 38.1% of<jats:named-content content-type=\"genus-species\">Corynebacterium<\/jats:named-content>isolates were susceptible to ciprofloxacin and trimethoprim-sulfamethoxazole, respectively. Our data show much lower susceptibility to penicillin than previously reported in the literature and an increasing number of isolates resistant to daptomycin, highlighting the need for continued antibiotic surveillance studies for appropriate patient management and treatment success.<\/jats:p>","DOI":"10.1128\/aac.01776-17","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T08:32:39Z","timestamp":1516005159000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["<i>In Vitro<\/i>Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016"],"prefix":"10.1128","volume":"62","author":[{"given":"Alefiya","family":"Neemuchwala","sequence":"first","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Soares","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithusha","family":"Ravirajan","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-2037","authenticated-orcid":false,"given":"Alex","family":"Marchand-Austin","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne V.","family":"Kus","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir N.","family":"Patel","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.1.125"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2211.160141"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00796-12"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinmicnews.2015.11.003"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/9781555816728.ch26","volume-title":"Manual of clinical microbiology","author":"Funke G","year":"2011","unstructured":"Funke G, Bernard K. 2011. Coryneform Gram-positive rods, p 413\u201342. In Versalovic J, Caroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed, vol 1. ASM Press, Washington, DC.","edition":"10"},{"key":"e_1_3_3_7_2","volume-title":"CLSI guideline M45","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd ed. CLSI guideline M45. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2874"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.208"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2015.530"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.6.1054"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-765X.2009.02553.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2671"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S74795"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01398.x"},{"key":"e_1_3_3_16_2","first-page":"7","article-title":"Ciprofloxacin-resistant Corynebacterium glucuronolyticum as a cause of male urethritis syndrome","volume":"2","author":"Me\u0161trovi\u0107 T","year":"2014","unstructured":"Me\u0161trovi\u0107 T, Sviben M, Profozi\u0107 Z, Bedeni\u0107 B, Ljubin-Sternak S. 2014. Ciprofloxacin-resistant Corynebacterium glucuronolyticum as a cause of male urethritis syndrome. JMM Case Rep 2:7.","journal-title":"JMM Case Rep"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02023.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167856"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr513"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00457-09"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2188-6"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00046-12"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0208"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00705-17"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01129-07"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.11.001"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2014.46.4.261"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1997.tb00470.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12197"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.7577"},{"key":"e_1_3_3_31_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2017","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01776-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01776-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:00:23Z","timestamp":1660312823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01776-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.01776-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01776-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01776-17"}}